SOTIO is conducting a multicenter open-label Phase 1/1b AURELIO-03 study (NCT04234113) to evaluate the safety and preliminary efficacy of nanrilkefusp alfa (formerly SOT101) as monotherapy and in combination with pembrolizumab in patients with selected relapsed/refractory advanced/metastatic solid tumors. Monotherapy and combination therapy dose escalation have been completed, RP2D defined, monotherapy efficacy extension in three selected indications is ongoing. The trial enrolls patients at leading institutions in the U.S. and EU.